Last reviewed · How we verify
Harms of Hepatocellular Carcinoma Surveillance
This study leverage a multi-center randomized controlled trial assessing screening-related benefits (i.e. early tumor detection, treatment eligibility, and overall survival) among a racially and socioeconomically diverse population of patients with cirrhosis. However, the randomized controlled trial was not budgeted to assess hepatocellular carcinoma screening-related harms. The goal of this study is to quantify physical, financial, and psychosocial harms across three healthcare settings.
Details
| Lead sponsor | University of Texas Southwestern Medical Center |
|---|---|
| Status | COMPLETED |
| Enrolment | 2871 |
| Start date | Sun Apr 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Jun 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Carcinoma, Hepatocellular
Interventions
- Prospective Longitudinal Data
- Surveys and Semi-structured Interviews
Countries
United States